Avammune Therapeutics

First-in-class small molecule inhibitors targeting ADAR1 and ENPP1 for enhanced cancer treatment efficacy.

HQ location

Philadelphia, United States

Website

Unlock the full power of analytics with a premium account

Track company size and historic growth

Track team composition and strength

Track website visits and app downloads

Tech stackLearn more about the technologies and tools that this company uses.